Please see my CV for a full list of publications.
Selected peer-reviewed publications
da Silva RGL (2026) What to look at before you get there? A pre-fieldwork virtual methodology for studying a community of scientists. Science, Technology & Society (Sage Publications). Forthcoming.
Greco LF, da Silva RGL, de Campos, AS, da Costa JP (2026) 'Well... we keep adapting our lab': Interconnected factors shaping vaccine R&D and production capacity in Brazil. Global Public Health, 21(1). DOI: 10.1080/17441692.2026.2614156
da Silva RGL et. al. (2025) Alternative Expertise Network and Contested Illness in Global Health: Long Covid in Brazil. Sociology of Health and Illness. DOI: 10.1111/1467-9566.70079
da Silva RGL. (2024) The advancement of artificial intelligence in biomedical research and health innovation: challenges and opportunities in emerging economies. BMC Globalization & Health 20, 44. DOI: 10.1186/s12992-024-01049-5
da Silva RGL et. al. (2024) How do molecular systems engineering scientists frame the ethics of their research? AJOB Empirical Bioethics DOI: 10.1080/23294515.2024.2302994
da Silva, RGL, Blasimme A. (2023) From lab to society: Fostering clinical translation of molecular systems engineering. Bioengineering and Translational Medicine. 2023; e10564. DOI: 10.1002/btm2.10564.
da Silva, RGL, Au L. (2022) Blind Spots of Sociotechnical Imaginaries: Covid-19 Skepticism in Brazil, United Kingdom and the United States. Science Technology and Society. 27(4):1-19. DOI: 10.1177/09717218221125217
da Silva RGL et. al. (2022). The industry of monoclonal antibodies in Brazil: public policies as instruments of technology upgrading. Science and Public Policy, scac047, DOI: 10.1093/scipol/scac047
da Silva RGL et. al. (2021). Rethinking approaches of science, technology, and innovation in healthcare during the COVID-19 pandemic: the challenge of translating knowledge infrastructures to public needs. Health Research Policy and Systems 19, 104. https://doi.org/10.1186/s12961-021-00760-8
da Silva RGL et. al. (2020). University participation in the production of molecular diagnostic tests for the novel coronavirus in Brazil: the response to health challenges. Cadernos de Saude Publica, 36 (6) 26.